#rvnc

REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC) Files An 8-K Results of Operations and Financial Condition

REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC) Files An 8-K Results of Operations and Financial Condition ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On January 5, 2017, Revance Therapeutics, Inc. (the Company) issued a press release providing clinical milestones for DaxibotulinumtoxinA for Injection (RT002) and financial outlook for 2017. The Company also announced its unaudited December…

Ensco plc (NYSE:ESV) Files An 8-K Entry into a Material Definitive Agreement

Ensco plc (NYSE:ESV) Files An 8-K Entry into a Material Definitive Agreement Item 1.01 Entry into a Material Definitive Agreement Item 2.03 Creation of a Direct Financial Obligation Item 9.01 Financial Statements and Exhibits EXHIBIT INDEX Fourth Amendment to the Fourth Amended and Restated Credit Agreement, dated as of December 15, 2016, by and among Ensco plc, and Pride International, Inc., the…